Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02963922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
February 6, 2017
Completion date
September 25, 2018
Enrollment
396 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

metabolism and nutrition disorder, obesity